Caris Life Sciences (NASDAQ:CAI) Stock Rating Reaffirmed as “Buy” by BTIG Research

Caris Life Sciences (NASDAQ:CAI)‘s stock had its “buy” rating reiterated by BTIG Research in a note issued to investors on Thursday, Benzinga reports. They presently have a $38.00 price target on the stock. BTIG Research‘s price target would indicate a potential upside of 50.61% from the stock’s current price.

Other research analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. boosted their price target on shares of Caris Life Sciences from $25.00 to $35.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. Canaccord Genuity Group raised their price objective on shares of Caris Life Sciences from $22.00 to $30.00 and gave the company a “hold” rating in a report on Monday, October 19th. Weiss Ratings cut shares of Caris Life Sciences from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, October 2nd. UBS Group set a $38.00 target price on shares of Caris Life Sciences in a research note on Thursday. Finally, Evercore reissued an “outperform” rating and issued a $26.00 target price on shares of Caris Life Sciences in a report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Caris Life Sciences has a consensus rating of “Moderate Buy” and an average target price of $30.82.

Caris Life Sciences Trading Down 3.1%

NASDAQ:CAI traded down $0.80 during trading hours on Thursday, reaching $25.23. 10,287,488 shares of the stock were exchanged, compared to its average volume of 3,532,322. The company has a quick ratio of 4.88, a current ratio of 5.53 and a debt-to-equity ratio of 0.66. The business has a 50-day moving average of $29.48 and a two-hundred day moving average of $21.74. Caris Life Sciences has a twelve month low of $14.19 and a twelve month high of $36.50. The company has a market capitalization of $7.13 billion, a price-to-earnings ratio of 76.45 and a beta of 0.71.

Caris Life Sciences (NASDAQ:CAI) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.03 by $0.02. Caris Life Sciences had a net margin of 10.62% and a return on equity of 18.77%. The company had revenue of $275.36 million during the quarter. During the same period in the prior year, the business earned $0.08 EPS. The business’s quarterly revenue was up 27.0% on a year-over-year basis. On average, equities analysts predict that Caris Life Sciences will post 0.13 EPS for the current year.

Insider Buying and Selling at Caris Life Sciences

In other Caris Life Sciences news, insider Brian Brille sold 400,000 shares of the company’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $30.33, for a total value of $12,132,000.00. Following the completion of the transaction, the insider owned 230,303 shares in the company, valued at $6,985,089.99. This represents a 63.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, President David Spetzler sold 478,000 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $24.86, for a total value of $11,883,080.00. Following the transaction, the president directly owned 1,052,083 shares in the company, valued at approximately $26,154,783.38. The trade was a 31.24% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 1,004,712 shares of company stock worth $27,205,419 over the last 90 days. Corporate insiders own 50.00% of the company’s stock.

Institutional Investors Weigh In On Caris Life Sciences

Several large investors have recently modified their holdings of CAI. Braidwell LP raised its position in Caris Life Sciences by 3.1% in the 2nd quarter. Braidwell LP now owns 8,256,032 shares of the company’s stock valued at $147,122,000 after purchasing an additional 246,585 shares during the last quarter. PointState Capital LP purchased a new stake in Caris Life Sciences during the 2nd quarter valued at approximately $121,690,000. BlackRock Inc. acquired a new stake in Caris Life Sciences during the 2nd quarter worth approximately $98,666,000. Canada Pension Plan Investment Board acquired a new stake in Caris Life Sciences during the 2nd quarter worth approximately $24,502,000. Finally, Amundi increased its holdings in shares of Caris Life Sciences by 5,709.5% in the second quarter. Amundi now owns 1,218,364 shares of the company’s stock valued at $21,711,000 after purchasing an additional 1,197,392 shares during the period.

Caris Life Sciences News Summary

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Citigroup raised its price target to $36 from $28 and maintained a Buy rating. BTIG Research also reiterated Buy, with a $38 target. Citigroup rating BTIG rating
• Positive Sentiment: Goldman Sachs stuck with its Buy rating, adding to the favorable analyst sentiment around CAI. Goldman Sachs rating
• Positive Sentiment: Third-quarter revenue grew 27% year over year to $275.36 million, while EPS of $0.05 beat the $0.03 consensus. Caris also raised its fiscal 2026 outlook, supporting expectations for continued growth. Q3 results and outlook
• Negative Sentiment: Despite the revenue growth and EPS beat, net income declined 37% year over year, with higher expenses weighing on profitability. EPS was also below the $0.08 reported a year earlier, a potential concern for investors focused on margins. Profit decline report

Caris Life Sciences Company Profile

Caris Life Sciences is a biotechnology and precision-medicine company that uses molecular profiling and artificial intelligence to support cancer diagnosis, treatment selection and drug development. The company analyzes tumor and blood samples to identify genomic, molecular and immune characteristics that may help physicians better understand a patient’s disease and select targeted therapies.

Its offerings include comprehensive tumor profiling, liquid-biopsy testing and data-driven clinical decision-support tools.